Cumberland Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2307701092
USD
2.35
0.19 (8.8%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Cumberland Pharmaceuticals, Inc. stock-summary
stock-summary
Cumberland Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).
Company Coordinates stock-summary
Company Details
2525 W End Ave Ste 950 , NASHVILLE TN : 37203-1608
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 7 Schemes (7.66%)

Foreign Institutions

Held by 4 Foreign Institutions (0.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. A. Kazimi
Chairman of the Board, Chief Executive Officer
Mr. Martin Cearnal
Executive Vice President, Chief Commercial Officer, Director
Dr. Gordon Bernard
Independent Director
Mr. Joseph Galante
Independent Director
Mr. Jonathan Griggs
Independent Director
Mr. Joey Jacobs
Independent Director
Mr. James Jones
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
11 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 50 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.37

stock-summary
Return on Equity

-10.96%

stock-summary
Price to Book

1.77